Ipilimumab (Yervoy) is a checkpoint inhibitor drug that blocks CTLA-4. It is a treatment for advanced melanoma and advanced renal cell cancer. Therapeutic Solutions International Awarded Landmark Patent for Cancer and COVID-19 Treatment
Numerous drugs such as Optivo®, Yervoy®, and Keytruda®, have been approved by the FDA for treatment of cancers by boosting immunity though blocking immune inhibiting mechanisms. This class of drugs, called "checkpoint inhibitors" represent a 15.2 billion dollar a year market.
Therapeutic Solutions International Reports its NanoStilbene™ Nutraceutical Product Enhances Efficacy of FDA Cleared Cancer Immunotherapy in Animal Model of Cancer
NanoStilbene™ nutraceutical product [1] together with anti-CTLA4 antibody, which is the mouse equivalent of Ipilimumab (Yervoy®), an FDA cleared immunotherapeutic which belongs to the family of drugs called "checkpoint inhibitors". The new data supports the possibility that NanoStilbene™, a proprietary formulation of pterostilbene [2], may increase effectiveness of drugs that activate the immune system to kill cancer.